NAMS (STOCKS)
NewAmsterdam Pharma Company N.V. Ordinary Shares
$34.860000
+0.620000 (+1.81%)
Prev close: $34.240000
Company Information
- Exchange
- XNAS
- Sector
- Commercial Services
- Industry
- Miscellaneous Commercial Services
- CEO
- Michael H. Davidson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,953.94M
- Employees
- 77
- P/E (TTM)
- -17.07
- P/B (TTM)
- 5.32
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
10
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.61 | $-0.40 | -0.2059 | -50.95% |
|
Jun 2025 (Q2)
|
$-0.15 | $-0.50 | +0.3515 | +70.09% |
|
Mar 2025 (Q1)
|
$-0.34 | $-0.50 | +0.1575 | +31.66% |
|
Dec 2024 (Q4)
|
$-0.93 | $-0.50 | -0.4343 | -87.61% |
Financial Statements
| Revenues | $35.24M |
| Benefits Costs and Expenses | $256.32M |
| Costs And Expenses | $256.32M |
| Operating Expenses | $238.18M |
| Selling, General, and Administrative Expenses | $100.04M |
| Depreciation and Amortization | $458.00K |
| Research and Development | $138.13M |
| Operating Income/Loss | -$202.93M |
| Income/Loss From Continuing Operations After Tax | -$221.07M |
| Income/Loss From Continuing Operations Before Tax | -$221.07M |
| Net Income/Loss | -$221.07M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$221.07M |
| Net Income/Loss Available To Common Stockholders, Basic | -$221.07M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.04 |
| Diluted Earnings Per Share | -$2.04 |
| Basic Average Shares | 119,595,625 |
| Diluted Average Shares | 119,595,625 |
| Assets | $786.43M |
| Current Assets | $732.33M |
| Noncurrent Assets | $54.10M |
| Fixed Assets | $323.00K |
| Other Non-current Assets | $53.78M |
| Liabilities | $58.36M |
| Current Liabilities | $58.27M |
| Accounts Payable | $3.63M |
| Other Current Liabilities | $54.64M |
| Noncurrent Liabilities | $85.00K |
| Equity | $728.07M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $728.07M |
| Liabilities And Equity | $786.43M |
| Net Cash Flow From Operating Activities | -$144.39M |
| Net Cash Flow From Operating Activities, Continuing | -$144.39M |
| Net Cash Flow From Investing Activities | -$215.95M |
| Net Cash Flow From Investing Activities, Continuing | -$215.95M |
| Net Cash Flow From Financing Activities | $472.45M |
| Net Cash Flow From Financing Activities, Continuing | $472.45M |
| Net Cash Flow | $112.10M |
| Net Cash Flow, Continuing | $112.10M |
| Comprehensive Income/Loss | -$220.86M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$220.86M |
| Other Comprehensive Income/Loss | $218.00K |